SCHEMBL6436852

SCHEMBL6436852

CCCc1ccc2cc3ccccc3cc2n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
GPBAR1 Q8TDU6 4/20 0.43
CYSLTR1 Q9Y271 4/20 0.43
TERT O14746 2/20 0.43
CYSLTR2 Q9NS75 2/20 0.42
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
GLA P06280 1/20 0.40
MAPT P10636 1/20 0.40
ACHE P22303 1/20 0.40
PDE10A Q9Y233 3/20 0.40
GRM1 Q13255 1/20 0.39
TLR8 Q9NR97 1/20 0.39
HTR3A P46098 1/20 0.39
CYP1A2 P05177 1/20 0.39
GAA P10253 1/20 0.39
NQO2 P16083 1/20 0.39
ELANE P08246 1/20 0.39
APP P05067 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725176 0.82 PDE10A (0.54) KDM4EGPBAR1CYSLTR1CYSLTR2ALDH1A1
Iodide SCHEMBL1343671 0.81 PDE10A (0.53) KDM4EGPBAR1CYSLTR1CYSLTR2ALDH1A1
SCHEMBL29047068 0.81 PDE10A (0.53) KDM4EGPBAR1CYSLTR1CYSLTR2ALDH1A1
SCHEMBL28709736 0.76 PDE10A (0.49) KDM4EGPBAR1CYSLTR1CYSLTR2PDE10A
SCHEMBL28580709 0.76 PDE10A (0.53) KDM4EGPBAR1CYSLTR1CYSLTR2ALDH1A1
SCHEMBL10910525 0.76 GPBAR1 (0.51) GPBAR1CYSLTR1CYSLTR2ALDH1A1HPGD
SCHEMBL12570780 0.74 CYP1A2 (0.55) KDM4EALDH1A1MAPTPDE10AGRM1
SCHEMBL14128956 0.74 PDE10A (0.49) KDM4EHPGDMAPTPDE10AHTR3A
Sulfuric Acid SCHEMBL28294778 0.74 CYP1A2 (0.50) KDM4EGPBAR1CYSLTR1CYSLTR2MAPT
SCHEMBL14127808 0.74 NCF1 (0.56) KDM4EALDH1A1HPGDMAPTPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050037090-A1 Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent MCKEARN JOHN P (US) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037090-A1 Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent PTGS2, PTGES2, PTGS1 KDM4E 3162/4885GPBAR1 1151/4885CYSLTR1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.